Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Stem Cell Research

Free Subscription Articles published in Leuk Lymphoma Retrieve available abstracts of 73 articles: HTML format

Single Articles

May 2024
1. VON DEM BORNE PA, Kemps-Mols BM, de Wreede LC, van Beek AA, et al
   The degree of HLA matching determines the incidence of cytokine release syndrome and associated nonrelapse mortality in matched related and unrelated allogeneic stem cell transplantation with post-transplant cyclophosphamide.
   Leuk Lymphoma. 2024 May 6:1-11. doi: 10.1080/10428194.2024.2344060.
   PubMed     Abstract available
   
   
   February 2024
2. BARAJAS ORDONEZ F, Wolleschak D, Zeller Y, Hinnerichs M, et al
   Parameters of body composition do not predict survival in patients with multiple myeloma undergoing autologous stem cell transplantation.
   Leuk Lymphoma. 2024 Feb 21:1-8. doi: 10.1080/10428194.2024.2319226.
   PubMed     Abstract available
   
   
   
3. TANG K, Lipton JH
   Stem cell allografting for chronic Myeloid leukemia in the tyrosine kinase era - forgotten but not gone.
   Leuk Lymphoma. 2024 Feb 9:1-10. doi: 10.1080/10428194.2024.2313626.
   PubMed     Abstract available
   
   
   January 2024
4. VIVIANI S, Vanazzi A, Frassoni S, Rusconi C, et al
   High-dose chemotherapy and autologous stem cell transplant as first salvage treatment for relapsed or refractory Hodgkin Lymphoma in the era of PET-adapted strategies.
   Leuk Lymphoma. 2024 Jan 2:1-12. doi: 10.1080/10428194.2023.2298273.
   PubMed     Abstract available
   
   
   December 2023
5. ZHANG F, Hu GH, Zhang LP, Xu LP, et al
   Outcomes of haploidentical hematopoietic stem cell transplantation with 'Beijing protocol' in pediatric myeloid neoplasms post cytotoxic therapy: a case series study.
   Leuk Lymphoma. 2023 Dec 3:1-6. doi: 10.1080/10428194.2023.2281276.
   PubMed    
   
   
   November 2023
6. LAI X, Xiao J, Wang T, Hou C, et al
   Prognostic significance of persisting DNMT3A, ASXL1, and TET2 mutation burden in acute myeloid leukemia patients with allogeneic hematopoietic stem cell transplantation during complete remission.
   Leuk Lymphoma. 2023 Nov 22:1-9. doi: 10.1080/10428194.2023.2284089.
   PubMed     Abstract available
   
   
   
7. VERSTRAETE E, Baumann C, Rousseau H, Campidelli A, et al
   Comparison of two reduced intensity conditioning regimens: Flu-Bu2 versus RIC-TBF in allogeneic hematopoietic stem cell transplantation.
   Leuk Lymphoma. 2023 Nov 21:1-4. doi: 10.1080/10428194.2023.2281269.
   PubMed    
   
   
   
8. ITONAGA H, Kato T, Sawayama Y, Katsuoka S, et al
   RAISING revealed a heterogenous pattern of HTLV-1 clonality after HLA-haploidentical peripheral blood stem cell transplantation for ATL.
   Leuk Lymphoma. 2023 Nov 1:1-4. doi: 10.1080/10428194.2023.2276058.
   PubMed    
   
   
   October 2023
9. MERIC N, Albayrak E, Gulbas Z, Kocabas F, et al
   MEIS inhibitors reduce the viability of primary leukemia cells and Stem cells by inducing apoptosis.
   Leuk Lymphoma. 2023 Oct 30:1-12. doi: 10.1080/10428194.2023.2275532.
   PubMed     Abstract available
   
   
   September 2023
10. LI L, Zhang R, Cao W, Bian Z, et al
    Comparative analysis of hypomethylating agents as maintenance therapy after allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
    Leuk Lymphoma. 2023 Sep 21:1-10. doi: 10.1080/10428194.2023.2252948.
    PubMed     Abstract available
    
    
    
11. GAULIN C, Craig F, Fortin Ensign S, Robetorye R, et al
    Allogeneic hematopoietic stem cell transplantation in adults with dendritic/histiocytic neoplasms.
    Leuk Lymphoma. 2023 Sep 7:1-4. doi: 10.1080/10428194.2023.2255707.
    PubMed    
    
    
    
12. PLATE M, Jessurun J, van Besien K
    Immune reconstitution inflammatory syndrome in a patient with M.haemophilum infection after allogeneic hematopoietic stem cell transplantation.
    Leuk Lymphoma. 2023 Sep 7:1-3. doi: 10.1080/10428194.2023.2254875.
    PubMed    
    
    
    
13. ELEUTHERAKIS PAPAIAKOVOU E, Terpos E, Kanellias N, Migkou M, et al
    Impact of daratumumab on stem cell mobilization and collection, engraftment and early post-transplant complications among multiple myeloma patients undergoing autologous stem cell transplantation.
    Leuk Lymphoma. 2023 Sep 1:1-8. doi: 10.1080/10428194.2023.2253479.
    PubMed     Abstract available
    
    
    August 2023
14. VELY A, Couturier MA, Delepine P, Le Calloch R, et al
    Comparison of efficacy and toxicity according to etoposide and cytarabine dosing in BEAM conditioning followed by autologous stem cell transplantation in Hodgkin lymphoma.
    Leuk Lymphoma. 2023 Aug 24:1-10. doi: 10.1080/10428194.2023.2251073.
    PubMed     Abstract available
    
    
    
15. KENKRE VP, Bradley K, Milton A, Burkholder JK, et al
    TCR-alpha/beta and CD19 depleted stem cell grafts from haploidentical donors for allogeneic transplantation in patients with relapsed lymphoma: a single-center experience.
    Leuk Lymphoma. 2023 Aug 10:1-5. doi: 10.1080/10428194.2023.2240918.
    PubMed    
    
    
    
16. LEW TE, Cliff ERS, Dickinson M, Tam CS, et al
    Allogeneic stem cell transplantation achieves long-term remissions in mantle cell lymphoma, including in TP53-mutated disease.
    Leuk Lymphoma. 2023 Aug 2:1-9. doi: 10.1080/10428194.2023.2241095.
    PubMed     Abstract available
    
    
    July 2023
17. CHEN H, Zhao X, Pan W, Xiao H, et al
    Integrated genomic and single-cell transcriptomic analyses reveal clonal evolution and immune signature in donor cell leukemia after haploidentical allogeneic hematopoietic stem cell transplantation.
    Leuk Lymphoma. 2023 Jul 10:1-8. doi: 10.1080/10428194.2023.2232493.
    PubMed     Abstract available
    
    
    June 2023
18. WOLFF L, Clottu A, Mamez AC, Ribi C, et al
    Myositis manifesting as respiratory insufficiency with anti-RNA polymerase III antibodies: an unusual presentation of graft-versus-host disease.
    Leuk Lymphoma. 2023 Jun 7:1-4. doi: 10.1080/10428194.2023.2220452.
    PubMed    
    
    
    
19. NESR G, Shah R, Kyriakou C, Sive J, et al
    Impact of timing of stem cell return following high dose melphalan in multiple myeloma patients with renal impairment: a single center experience.
    Leuk Lymphoma. 2023 Jun 1:1-7. doi: 10.1080/10428194.2023.2216817.
    PubMed     Abstract available
    
    
    May 2023
20. SHARMA N, Benson E, Zhao Q, Nunnelee J, et al
    Survival outcomes following autologous stem cell transplant with melphalan 140mg/m(2) versus 200mg/m(2) preparative regimens in patients with multiple myeloma.
    Leuk Lymphoma. 2023 May 18:1-7. doi: 10.1080/10428194.2023.2213366.
    PubMed     Abstract available
    
    
    
21. MAGEAU A, Ambert-Balay K, Boutolleau D, Schuffenecker I, et al
    Norovirus and sapovirus infections after allogeneic hematopoietic stem cell transplantation: is it worth it to look for them?
    Leuk Lymphoma. 2023 May 10:1-9. doi: 10.1080/10428194.2023.2211186.
    PubMed     Abstract available
    
    
    
22. PLANTE ME, Feng X, Boudreault JS
    Single-center retrospective study assessing the efficacy and safety of BeEAM (bendamustine, etoposide, cytarabine, melphalan) as conditioning regimen for autologous hematopoietic stem cell transplantation.
    Leuk Lymphoma. 2023 May 8:1-9. doi: 10.1080/10428194.2023.2203790.
    PubMed     Abstract available
    
    
    
23. MODI D, Alkassis S, Kim S, Kin A, et al
    Allogeneic stem cell transplant outcomes between TBI-containing reduced intensity and myeloablative conditioning regimens for ALL in complete remission.
    Leuk Lymphoma. 2023 May 8:1-10. doi: 10.1080/10428194.2023.2206181.
    PubMed     Abstract available
    
    
    April 2023
24. AKHMEDOV M, Klyasova G, Kuzmina L, Fedorova A, et al
    Impact of fluoroquinolone administration and gut mucosal colonization on the risk of pre-engraftment bloodstream infections after allogeneic hematopoietic cell transplantation.
    Leuk Lymphoma. 2023 Apr 22:1-10. doi: 10.1080/10428194.2023.2197532.
    PubMed     Abstract available
    
    
    
25. MEHYAR LS, Hartog L, Kahwash SB, Abu-Arja R, et al
    Long term survivor of MOZ-p300 therapy-related acute myeloid leukemia after matched unrelated donor bone marrow transplantation.
    Leuk Lymphoma. 2023 Apr 20:1-4. doi: 10.1080/10428194.2023.2203287.
    PubMed    
    
    
    
26. BERTON G, Arcani R, Tichadou A, Farnault L, et al
    Therapy-related myeloid neoplasms after 177Lu-DOTATATE therapy for metastatic neuroendocrine neoplasia: CPX-351 consolidated by allogeneic stem cells transplantation as applicable therapeutic strategy.
    Leuk Lymphoma. 2023 Apr 12:1-3. doi: 10.1080/10428194.2023.2199896.
    PubMed    
    
    
    February 2023
27. CHOQUETTE T, Henson ES, Yang X, Johnston JB, et al
    A novel method to investigate drug resistance in the chronic lymphocytic leukemia (CLL) microenvironment: Analysis of CLL Cellular Environment and Response (ACCER).
    Leuk Lymphoma. 2023 Feb 19:1-13. doi: 10.1080/10428194.2023.2171729.
    PubMed     Abstract available
    
    
    January 2023
28. LIN M, Wu X, Zhang L, Li L, et al
    Fotemustine, etoposide, cytarabine, and cyclophosphamide (FEAC) conditioning regimen for autologous stem cell transplantation in lymphoma.
    Leuk Lymphoma. 2023 Jan 19:1-8. doi: 10.1080/10428194.2023.2167492.
    PubMed     Abstract available
    
    
    
29. GAUT D, Oliai C, Mead M
    Outcomes of allogeneic hematopoietic stem cell transplantation in secondary central nervous system lymphoma: a case series.
    Leuk Lymphoma. 2023 Jan 17:1-4. doi: 10.1080/10428194.2022.2151839.
    PubMed    
    
    
    
30. KALOYANNIDIS P, Al Zayer M, Al Darweesh M, Al Batran M, et al
    Brentuximab vedotin plus bendamustine versus platinum-based regimens as 1st salvage therapy and 'bridge' to autologous hematopoietic stem cell transplantation for relapsed/refractory Hodgkin lymphoma.
    Leuk Lymphoma. 2023 Jan 11:1-4. doi: 10.1080/10428194.2022.2164195.
    PubMed    
    
    
    November 2022
31. MOYER AM, Hashmi SK, Kroning CM, Patnaik M, et al
    Clinical impact of KIR haplotypes in 10/10 HLA-matched unrelated donor-recipient pairs undergoing allogeneic hematopoietic stem cell transplantation.
    Leuk Lymphoma. 2022 Nov 30:1-8. doi: 10.1080/10428194.2022.2151838.
    PubMed     Abstract available
    
    
    
32. KUMAR L, Sahoo RK, Kumar S, Baa AK, et al
    Autologous stem cell transplant for multiple myeloma: Impact of melphalan dose on the transplant outcome.
    Leuk Lymphoma. 2022 Nov 23:1-10. doi: 10.1080/10428194.2022.2148214.
    PubMed     Abstract available
    
    
    
33. PIANKO MJ
    Impact of diet and antibiotics on gut microbiota and outcomes in patients with multiple myeloma treated with autologous hematopoietic stem cell transplantation.
    Leuk Lymphoma. 2022 Nov 18:1-2. doi: 10.1080/10428194.2022.2148219.
    PubMed    
    
    
    
34. MCCLELLAND J, Wong E, Grigg A
    Optimizing the oral dose of cyclosporine with concomitant posaconazole post stem cell allograft.
    Leuk Lymphoma. 2022 Nov 11:1-5. doi: 10.1080/10428194.2022.2142054.
    PubMed     Abstract available
    
    
    
35. KREFT A, Schulze L, Ries I, Schindeldecker M, et al
    Histological diagnosis of acute graft-versus-host disease in different sites of the upper gastrointestinal tract with correlation to endoscopic findings.
    Leuk Lymphoma. 2022 Nov 6:1-7. doi: 10.1080/10428194.2022.2142056.
    PubMed     Abstract available
    
    
    
36. MIKULSKI D, Koscielny K, Nowicki M, Wawrzyniak E, et al
    Neutrophil to lymphocyte ratio (NLR) impact on the progression-free survival and overall survival of multiple myeloma patients treated with high-dose chemotherapy and autologous stem cell transplantation.
    Leuk Lymphoma. 2022 Nov 1:1-9. doi: 10.1080/10428194.2022.2136946.
    PubMed     Abstract available
    
    
    October 2022
37. STEWART T, Dowling M, Janson B, Siderov J, et al
    Acute kidney injury in patients receiving high-dose etoposide phosphate as conditioning prior to hematopoietic stem cell transplantation in hematologic malignancies may be associated with elevated body mass index.
    Leuk Lymphoma. 2022 Oct 25:1-3. doi: 10.1080/10428194.2022.2136945.
    PubMed    
    
    
    
38. GARDENSWARTZ A, Mehta B, El-Mallawany NK, van de Ven C, et al
    Safety and efficacy of combinatorial therapy utilizing myeloablative conditioning and autologous stem cell transplantation, targeted immunotherapy, and reduced intensity conditioning and allogeneic stem cell transplantation in children, adolescents, a
    Leuk Lymphoma. 2022 Oct 19:1-4. doi: 10.1080/10428194.2022.2133542.
    PubMed    
    
    
    
39. D'ANGELO C, Sudakaran S, Asimakopoulos F, Hematti P, et al
    Perturbation of the gut microbiome and association with outcomes following autologous stem cell transplantation in patients with multiple myeloma.
    Leuk Lymphoma. 2022 Oct 11:1-11. doi: 10.1080/10428194.2022.2131410.
    PubMed     Abstract available
    
    
    September 2022
40. VILLALBA A, Gonzalez-Rodriguez AP, Arzuaga-Mendez J, Puig N, et al
    Single versus tandem autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma and high-risk cytogenetics. A retrospective, open-label study of the PETHEMA/Spanish Myeloma Group (GEM).
    Leuk Lymphoma. 2022 Sep 20:1-10. doi: 10.1080/10428194.2022.2123229.
    PubMed     Abstract available
    
    
    
41. SHAHZAD M, Tariq E, Chaudhary SG, Anwar I, et al
    Outcomes with allogeneic hematopoietic stem cell transplantation in TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis.
    Leuk Lymphoma. 2022 Sep 15:1-9. doi: 10.1080/10428194.2022.2123228.
    PubMed     Abstract available
    
    
    
42. LU Y, Xiong M, Sun RJ, Zhang JP, et al
    Comparisons of unmanipulated haploidentical donor, unrelated cord blood donor and matched unrelated donor hematopoietic stem cell transplantation in pediatric acquired severe aplastic anemia: a single center study.
    Leuk Lymphoma. 2022 Sep 6:1-10. doi: 10.1080/10428194.2022.2118527.
    PubMed     Abstract available
    
    
    
43. LU Y, Sun RJ, Zhang JP, Xu F, et al
    Allogeneic hematopoietic stem cell transplantation with myeloablative conditioning regimen for blastic plasmacytoid dendritic cell neoplasm patients in complete remission: a single center study.
    Leuk Lymphoma. 2022 Sep 6:1-8. doi: 10.1080/10428194.2022.2118531.
    PubMed     Abstract available
    
    
    August 2022
44. TARANTO E, Redd R, Jeter E, McHugh K, et al
    Prognostic value of minimal residual disease among patients with classical Hodgkin lymphoma undergoing autologous stem cell transplantation.
    Leuk Lymphoma. 2022 Aug 7:1-6. doi: 10.1080/10428194.2022.2103808.
    PubMed     Abstract available
    
    
    July 2022
45. LOLLI G, Ursi M, Dicataldo M, Casadei B, et al
    Allogeneic stem cell transplantation is capable of healing a case of bone marrow aplasia following CAR-T cell therapy in a lymphoma patient.
    Leuk Lymphoma. 2022 Jul 22:1-3. doi: 10.1080/10428194.2022.2102622.
    PubMed    
    
    
    
46. ZAMA D, Mondardini MC, Petris MG, Amigoni A, et al
    Pediatric cancer and hematopoietic stem cell transplantation patients requiring renal replacement therapy: results of the retrospective nationwide AIEOP study.
    Leuk Lymphoma. 2022 Jul 12:1-8. doi: 10.1080/10428194.2022.2095628.
    PubMed     Abstract available
    
    
    June 2022
47. SERPENTI F, Sciume M, Galassi G, Saporiti G, et al
    Off-label venetoclax in combination with hypomethylating agents for post-allogeneic stem cell transplant acute myeloid leukemia relapse.
    Leuk Lymphoma. 2022 Jun 22:1-4. doi: 10.1080/10428194.2022.2090553.
    PubMed    
    
    
    
48. LIU Y, Qi L, Wang T, Zhou B, et al
    The clinical outcomes of mixed engraftment patients treated with haploidentical stem cells combined with umbilical cord blood transplantation.
    Leuk Lymphoma. 2022 Jun 18:1-5. doi: 10.1080/10428194.2022.2086245.
    PubMed    
    
    
    
49. HO M, Moscvin M, Low SK, Evans B, et al
    Risk factors for the development of orthostatic hypotension during autologous stem cell transplant in patients with multiple myeloma.
    Leuk Lymphoma. 2022 Jun 14:1-10. doi: 10.1080/10428194.2022.2084729.
    PubMed     Abstract available
    
    
    
50. LAHOUD OB, Landau H, Nguyen J, Devlin S, et al
    Continuous induction with lenalidomide/dexamethasone versus autologous stem cell transplantation in newly diagnosed multiple myeloma: a case for response-adapted approach.
    Leuk Lymphoma. 2022 Jun 1:1-10. doi: 10.1080/10428194.2022.2062347.
    PubMed     Abstract available
    
    
    May 2022
51. HOWELLS L, Chan WY, Sanchez E, Horder J, et al
    Patients with plasma cell disorders undergoing autologous stem cell transplant retain their humoral response to COVID-19 vaccination but falling titers emphasize the importance of re-vaccination.
    Leuk Lymphoma. 2022 May 14:1-5. doi: 10.1080/10428194.2022.2074989.
    PubMed    
    
    
    
52. GERTZ MA, Warsame R, Muchtar E, Buadi F, et al
    Lack of a caregiver is associated with shorter survival in myeloma patients undergoing autologous stem cell transplantation.
    Leuk Lymphoma. 2022 May 12:1-6. doi: 10.1080/10428194.2022.2074993.
    PubMed     Abstract available
    
    
    April 2022
53. PORRATA LF, Inwards DJ, Ansell SM, Micallef IN, et al
    Impact of autograft-absolute lymphocyte count on survival in double/triple hit lymphomas post-autologous stem cell transplantation.
    Leuk Lymphoma. 2022 Apr 28:1-8. doi: 10.1080/10428194.2022.2064988.
    PubMed     Abstract available
    
    
    
54. TAMAKI M, Nakasone H, Nakamura Y, Kawamura M, et al
    Risk factors and outcomes of definite or clinical idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation.
    Leuk Lymphoma. 2022 Apr 7:1-9. doi: 10.1080/10428194.2022.2057486.
    PubMed     Abstract available
    
    
    March 2022
55. PERKINS B, Showel M, Schoch L, Imus PH, et al
    CD34+ cell of origin for immunoglobulin heavy chain variable region unmutated, but not mutated, chronic lymphocytic leukemia.
    Leuk Lymphoma. 2022 Mar 27:1-7. doi: 10.1080/10428194.2022.2038375.
    PubMed     Abstract available
    
    
    February 2022
56. MUKHERJEE A, Milton DR, Jabbour EJ, Gulbis AM, et al
    Clinical outcome of allogeneic stem cell transplantation in patients with B-cell lymphoid malignancies following treatment with targeted small molecule inhibitors.
    Leuk Lymphoma. 2022 Feb 27:1-9. doi: 10.1080/10428194.2022.2043302.
    PubMed     Abstract available
    
    
    
57. KAMADA Y, Arima N, Hayashida M, Nakamura D, et al
    Prediction of the risk for graft versus host disease after allogeneic hematopoietic stem cell transplantation in patients treated with mogamulizumab.
    Leuk Lymphoma. 2022 Feb 27:1-7. doi: 10.1080/10428194.2022.2043300.
    PubMed     Abstract available
    
    
    
58. NAGAYAMA T, Fujiwara SI, Kikuchi T, Onda K, et al
    Impact of muscle mass loss assessed by computed tomography on the outcome of allogeneic stem cell transplantation.
    Leuk Lymphoma. 2022 Feb 14:1-7. doi: 10.1080/10428194.2022.2034159.
    PubMed     Abstract available
    
    
    January 2022
59. WANG SSY
    Relationship between leukaemic stem cells and hematopoietic stem cells and their clinical application.
    Leuk Lymphoma. 2022 Jan 22:1-10. doi: 10.1080/10428194.2022.2027401.
    PubMed     Abstract available
    
    
    
60. IKEDA D, Tsushima T, Fukumoto A, Kuzume A, et al
    Rapid liver atrophy and refractory ascites due to hepatoportal sclerosis in a patient after haploidentical stem cell transplantation.
    Leuk Lymphoma. 2022 Jan 12:1-4. doi: 10.1080/10428194.2022.2027400.
    PubMed    
    
    
    December 2021
61. LU Y, Zhao YL, Xiong M, Sun RJ, et al
    Unmanipulated haploidentical donor and matched unrelated donor hematopoietic stem cell transplantation in patients with paroxysmal nocturnal hemoglobinuria: a single-center study.
    Leuk Lymphoma. 2021 Dec 16:1-9. doi: 10.1080/10428194.2021.2015588.
    PubMed     Abstract available
    
    
    
62. SINGH V, Kim S, Deol A, Uberti JP, et al
    Allogeneic hematopoietic stem cell transplantation in T-cell lymphoma: a Meta-Analysis.
    Leuk Lymphoma. 2021 Dec 5:1-10. doi: 10.1080/10428194.2021.1999438.
    PubMed     Abstract available
    
    
    November 2021
63. PALMIERI R, Buccisano F, Arena V, Irno Consalvo MA, et al
    CD34 + CD38-CLL1+ leukemic stem cells persistence measured by multiparametric flow cytometry is a biomarker of poor prognosis in adult patients with acute myeloid leukemia.
    Leuk Lymphoma. 2021 Nov 21:1-5. doi: 10.1080/10428194.2021.2005042.
    PubMed    
    
    
    
64. HOSOI H, Matsuyama Y, Murata S, Mushino T, et al
    Prolonged Epstein-Barr virus reactivation coincident with chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
    Leuk Lymphoma. 2021 Nov 16:1-4. doi: 10.1080/10428194.2021.2005047.
    PubMed    
    
    
    
65. JADERSTEN M, Boriskina K, Lindholm C, Westrom S, et al
    Limited benefit in patients with MDS receiving venetoclax and azacitidine as a bridge to allogeneic stem cell transplantation.
    Leuk Lymphoma. 2021 Nov 15:1-4. doi: 10.1080/10428194.2021.2002319.
    PubMed    
    
    
    
66. SOARE DS, Radu E, Dumitru I, Vladareanu AM, et al
    Quantitative analyses of CD7, CD33, CD34, CD56, and CD123 within the FLT3-ITD/NPM1-MUT myeloblastic/monocytic bulk AML blastic populations.
    Leuk Lymphoma. 2021;62:2716-2726.
    PubMed     Abstract available
    
    
    October 2021
67. ALHOMOUD M, Williams A, Magro C, Van Besien K, et al
    Use of eculizumab in autologous hematopoietic stem cell transplantation-associated thrombotic microangiopathy in two adults.
    Leuk Lymphoma. 2021 Oct 20:1-5. doi: 10.1080/10428194.2021.1992625.
    PubMed    
    
    
    
68. ARCARI A, Morello L, Vallisa D, Marcheselli L, et al
    Allogeneic stem cell transplantation in patients with mantle cell lymphoma: results from the MANTLE-FIRST study on behalf of Fondazione Italiana Linfomi.
    Leuk Lymphoma. 2021 Oct 8:1-10. doi: 10.1080/10428194.2021.1961238.
    PubMed     Abstract available
    
    
    
69. KOO RM, Ritchie D
    Self-reliance or the generosity of others?: autologous versus allogeneic stem cell transplantation in high-risk Hodgkin lymphoma.
    Leuk Lymphoma. 2021;62:2303-2305.
    PubMed    
    
    
    September 2021
70. PAVIGLIANITI A, Sestili S, Bianchessi A, Memoli M, et al
    Stable pulmonary function after haploidentical stem cell transplantation with post-transplant cyclophosphamide: a single center experience.
    Leuk Lymphoma. 2021 Sep 29:1-7. doi: 10.1080/10428194.2021.1984460.
    PubMed     Abstract available
    
    
    
71. FULCHER J, Berardi P, Christou G, Villeneuve PJA, et al
    Nelarabine-containing regimen followed by daratumumab as an effective salvage therapy and bridge to allogeneic hematopoietic stem cell transplantation for primary refractory early T-cell precursor lymphoblastic leukemia.
    Leuk Lymphoma. 2021;62:2295-2297.
    PubMed    
    
    
    
72. ARORA S, Vachhani P, Bachiashvili K, Jamy O, et al
    Venetoclax with chemotherapy in relapse/refractory early T-cell precursor acute lymphoblastic leukemia.
    Leuk Lymphoma. 2021;62:2292-2294.
    PubMed    
    
    
    August 2021
73. WANG J, Yang L, Dao FT, Wang YZ, et al
    Prognostic significance of TIM-3 expression pattern at diagnosis in patients with t(8;21) acute myeloid leukemia.
    Leuk Lymphoma. 2021 Aug 18:1-10. doi: 10.1080/10428194.2021.1966785.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Stem Cell Research is free of charge.